John Byrd C MD

John Byrd C MD
ProfessorCollege of Medicinebyrd.96@osu.edu
B302 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-8330Fax: (614) 293-7526
  • Administrative
  • Leukemia Research

Research Description

Dr. Byrd’s research accomplishments relate best to work done between the laboratory and clinic (translational work) with several different therapeutic agents active in CLL and related leukemia and lymphoma. As a consequence of Dr. Byrd’s detailed laboratory and clinical work, therapeutic agents such as rituximab, alemtuzumab, and recently flavopiridol have been identified as effective agents for CLL. In particular, Dr. Byrd has and continues to be very active in development of therapeutic antibodies and other targeted agents because of his desire to work on non-toxic therapies for the treatment of leukemia.

Current Publications

  • Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar HNon-Hodgkin's Lymphomas, Version 4.2014.J Natl Compr Canc Netw 12 1282-303 9/1/2014
  • Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MAQuantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.J Pharm Biomed Anal 98 160-5 9/1/2014
  • Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA, Maddocks K, Ruppert AS, Browning R, Jones J, Flynn JA dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.Leuk Res 38 1025-9 9/1/2014
  • Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri FCirculating miRNA markers show promise as new prognosticators for multiple myeloma.Leukemia 28 1922-6 9/1/2014
  • Frankhouser DE, Murphy M, Blachly JS, Park J, Zoller MW, Ganbat JO, Curfman J, Byrd JC, Lin S, Marcucci G, Yan P, Bundschuh RPrEMeR-CG: Inferring Nucleotide Level DNA Methylation Values from MethylCap-Seq Data.Bioinformatics in press 8/31/2014
  • Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC, El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FTPKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.Blood 124 1481-91 8/28/2014
  • Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AKOtlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.Br J Haematol in press 8/22/2014
  • Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC, the LUCID trial investigatorsA randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.Br J Haematol in press 8/8/2014
  • Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JMEntering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician.J Clin Oncol in press 7/21/2014
  • Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, RESONATE Investigators, Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NEIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.N Engl J Med 371 213-23 7/17/2014
  • Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DV, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJMitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.Leukemia in press 7/3/2014
  • Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC, Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JRValidation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.Blood 124 42-8 7/3/2014
  • Zhong Y, Byrd JC, Dubovsky JAThe B-cell receptor pathway: a critical component of healthy and malignant immune biology.Semin Hematol 51 206-18 7/1/2014
  • Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N, Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LAThe CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.Leukemia 28 1501-10 7/1/2014
  • Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MATumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia.Leukemia in press 6/20/2014
  • MacDonald KP, Hill GR, Blazar BR, Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JCIncreased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.Blood 123 3988-98 6/19/2014
  • Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JCResistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.N Engl J Med 370 2286-94 6/12/2014
  • Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum WPhase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 55 1304-8 6/1/2014
  • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar HNon-Hodgkin's Lymphomas, Version 2.2014.J Natl Compr Canc Netw 12 916-46 6/1/2014
  • Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci GPhase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.Leuk Lymphoma 55 1332-6 6/1/2014
  • Flynn JM, Grever MR, Lozanski G, Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Johnson AJ, Muthusamy N, Heerema NA, Byrd JCImpact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.Leukemia 28 1365-8 6/1/2014
  • Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RRIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Blood 123 3390-7 5/29/2014
  • Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SEIdelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Blood 123 3406-13 5/29/2014
  • Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston NDA phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).Blood 123 3398-405 5/29/2014
  • Byrd JCChronic lymphocytic leukemia: state of the art and beyond.J Natl Compr Canc Netw 12 801-3 5/1/2014
  • Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JCOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.MAbs 6 749-55 5/1/2014
  • Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, Bhalla KNAuranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.Cancer Res 74 2520-32 5/1/2014
  • Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella R, Zhong Y, El-Gamal DSelinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.Leukemia 28 1158-63 5/1/2014
  • Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA, Alliance for Clinical Trials In Oncology (ACTION)Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.Br J Haematol 165 102-11 4/1/2014
  • Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JCIbrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.Blood 123 1957-60 3/20/2014
  • Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Yan F, Alinari L, Lustberg ME, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RAGenetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Jones JA, Byrd JCHow will B-cell-receptor-targeted therapies change future CLL therapy?Blood 123 1455-60 3/6/2014
  • Mertens D, Lichter P, Döhner H, Stilgenbauer S, Byrd JC, Zenz T, Plass C, Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR, Rassenti L, Kipps TJEvolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia.Cancer Discov 4 348-61 3/1/2014
  • Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RRA phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.Blood 123 1302-8 2/27/2014
  • Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJBruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).Blood 123 1207-13 2/20/2014
  • Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CDEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.J Clin Oncol 32 548-56 2/20/2014
  • Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy NA novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.Nanomedicine 10 393-400 2/1/2014
  • Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JCA phase I trial of flavopiridol in relapsed multiple myeloma.Cancer Chemother Pharmacol 73 249-57 2/1/2014
  • Byrd JCTraditional treatment approaches in chronic lymphocytic leukemia.Clin Adv Hematol Oncol 12 5-8 1/1/2014
  • Furman RR, Byrd JC, O'Brien SMUnmet needs in the treatment of chronic lymphocytic leukemia: general discussion.Clin Adv Hematol Oncol 12 11-3 1/1/2014
  • Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MASensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.J Pharm Biomed Anal 88 262-8 1/1/2014
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol 89 19-24 1/1/2014
  • Coutre SE, Sharman JP, Burger JA, O'Brien S, Furman RR, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JCIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.Lancet Oncol 15 48-58 1/1/2014
  • Lee LJ, Wu Y, Kwak KJ, Agarwal K, Marras A, Wang C, Mao Y, Huang X, Ma J, Yu B, Lee R, Vachani A, Marcucci G, Byrd JC, Muthusamy N, Otterson G, Huang K, Castro CE, Paulaitis M, Nana-Sinkam SPDetection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.Anal Chem 85 11265-74 12/3/2013
  • Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC, Johnson AJIdentification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies.Leuk Lymphoma 54 2685-92 12/1/2013
  • Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JCPatients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Leuk Lymphoma 54 2654-9 12/1/2013
  • Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy NLymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.Blood 122 3308-16 11/7/2013
  • Grant BW, Jung SH, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, Jones J, Leonard JP, Martin SE, Cheson BDA phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.Cancer 119 3797-804 11/1/2013
  • Singh R, Mortazavi A, Telu KH, Nagarajan P, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MRIncreasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis.Nucleic Acids Res 41 9284-95 11/1/2013
  • Zhong Y, Byrd JCIRF4(-/-)Vh11 mice: a novel mouse model of CLL.Blood 122 2769-70 10/17/2013
  • Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JCIbrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood 122 2539-49 10/10/2013
  • Harshman SW, Chen MM, Branson OE, Jacob NK, Johnson AJ, Byrd JC, Freitas MAIsolation and analysis of linker histones across cellular compartments.J Proteomics 91 595-604 10/8/2013
  • Blachly JS, Byrd JCEmerging drug profile: cyclin-dependent kinase inhibitors.Leuk Lymphoma 54 2133-43 10/1/2013
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JMCyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.Leuk Res 37 1195-9 10/1/2013
  • Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti DPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest 123 4144-57 10/1/2013
  • Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani SFcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.J Biol Chem 288 26800-9 9/13/2013
  • Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum WPharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 54 1996-2002 9/1/2013
  • Jacob NK, Lapalombella R, McGourty J, Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy NGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs 5 723-35 9/1/2013
  • Byrd JC, Lee LJ, Muthusamy N, Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJTargeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.Biomaterials 34 6185-93 8/1/2013
  • Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA, Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KSEarly versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Leuk Lymphoma 54 1658-64 8/1/2013
  • Byrd JC, Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Volinia S, Shapiro CL, Freitas MA, Croce CMIn vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.J Exp Med 210 951-68 5/6/2013
  • Gupta SV, Hertlein E, Lu Y, Sass EJ, Lapalombella R, Chen TL, Davis ME, Woyach JA, Lehman A, Jarjoura D, Byrd JC, Lucas DMThe proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Clin Cancer Res 19 2406-19 5/1/2013
  • Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci GTargeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.Clin Cancer Res 19 2355-67 5/1/2013
  • Stephens DM, Byrd JCImproving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy.Hematol Oncol Clin North Am 27 303-27 4/1/2013
  • Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci GIncreased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.Leukemia 27 871-8 4/1/2013
  • Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JCComparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.J Immunol 190 2702-11 3/15/2013
  • Mahoney E, Byrd JC, Johnson AJAutophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Autophagy 9 434-5 3/1/2013
  • Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M, National Comprehensive Cancer Network, Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJNon-Hodgkin's lymphomas, version 1.2013.J Natl Compr Canc Netw 11 257-72; quiz 273 3/1/2013
  • Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MAA pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Clin Cancer Res 19 1269-80 3/1/2013
  • Zhong Y, Byrd JCUGT2B17 as a disease accelerator in CLL.Blood 121 1067-8 2/14/2013
  • Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J, Appelbaum FR, Tallman MS, Belch AR, Morrison VA, Larson RA, Byrd JCImpact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.J Clin Oncol 31 440-7 2/1/2013
  • Zhang J, Grubor V, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni TGenetic heterogeneity of diffuse large B-cell lymphoma.Proc Natl Acad Sci U S A 110 1398-403 1/22/2013
  • Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy NMilatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.Clin Cancer Res 19 347-56 1/15/2013
  • Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, Jarjoura D, Marcucci G, Lee RJ, Byrd JC, Lee LJ, Muthusamy NTargeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.Blood 121 136-47 1/3/2013
  • Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G, Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZLenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.Blood 121 159-69 1/3/2013
  • Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu PC, Kulp SK, Byrd JC, Chen CSFunctional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.PLoS One 8 e67149 1/1/2013
  • Wei QX, Claus R, Hielscher T, Mertens D, Raval A, Oakes CC, Tanner SM, de la Chapelle A, Byrd JC, Stilgenbauer S, Plass CGermline allele-specific expression of DAPK1 in chronic lymphocytic leukemia.PLoS One 8 e55261 1/1/2013
  • Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci GIn vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.AAPS J 15 242-9 1/1/2013
  • Alachkar H, Santhanam R, Harb JG, Lucas DM, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G, Oaks JJ, Hickey CJ, Pan L, Kinghorn ADSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.J Hematol Oncol 6 21 1/1/2013
  • Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, Andritsos L, Lozanski A, Rassenti L, Zhao W, Jarvinen TM, Senter L, Croce CM, Symer DE, de la Chapelle A, Heerema NA, Byrd JCCharacterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.PLoS One 8 e76607 1/1/2013
  • Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Naganuma M, Dwyer MANon-Hodgkin's Lymphomas, version 3.2012.J Natl Compr Canc Netw 10 1487-98 12/1/2012
  • Rozewski DM, Herman SE, Towns WH 2nd, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D, Byrd JC, Johnson AJ, Phelps MAPharmacokinetics and tissue disposition of lenalidomide in mice.AAPS J 14 872-82 12/1/2012
  • Zhang X, Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Jones J, Bannerji R, Grever MR, Byrd JCThe novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.Leukemia 26 2554-7 12/1/2012
  • Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JCSelective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.Blood 120 4621-34 11/29/2012
  • Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien SPhase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma 53 2136-42 11/1/2012
  • Stephens DM, Byrd JCChronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches.Oncology (Williston Park) 26 1044-54 11/1/2012
  • Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE, Kramer J, Muthusamy N, Hunder N, Pagel JMA phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.Clin Cancer Res 18 5752-60 10/15/2012
  • Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LAComplex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.Br J Haematol 159 82-7 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu